POINT Biopharma Global Net Income

POINT Biopharma Global (PNT) currently reports a net income of $97M as of September 2023. That is below the Healthcare sector average of $16B. Use the charts on this page to explore POINT Biopharma Global's net income history and peer comparisons.

POINT Biopharma Global's net income of $97M is lower than the Healthcare sector average of $16B. That is roughly 99.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

POINT Biopharma Global reported $97M in net income as of September 2023. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $97M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for POINT Biopharma Global, and consider following PNT for alerts when major investors trade the stock.

POINT Biopharma Global is classified in the Healthcare sector. On net income, it currently shows $97M versus a sector average near $16B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PNT with unrelated industries.